304 filings
Page 12 of 16
6-K
4hu 44vz4x32cc
29 Aug 14
Current report (foreign)
12:00am
6-K
isu1nvvu
13 Aug 14
Current report (foreign)
12:00am
SC 13G
p7wk0kit0pt
8 Aug 14
GW Pharmaceuticals PLC
12:00am
6-K
aw4884t3
6 Aug 14
GW Pharmaceuticals plc Reports 2014 Third Quarter Financial Results
12:00am
6-K
5my2p 2ch3
26 Jun 14
Current report (foreign)
12:00am
6-K
cv7huy0h7mh
20 Jun 14
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totalling Approximately $148 Million on NASDAQ Global Market
12:00am
424B5
afbuscy
20 Jun 14
Prospectus supplement for primary offering
12:00am
FWP
p9vuw14rv1qc1afvxags
19 Jun 14
Free writing prospectus
12:00am
6-K
9df fmxa4t
18 Jun 14
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
12:00am
424B5
kd240rkpsnhz o4a
17 Jun 14
Prospectus supplement for primary offering
12:00am
6-K
9ro8yeb5oq
17 Jun 14
Current report (foreign)
12:00am
6-K
9rzviwn o9f05
9 Jun 14
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome
12:00am
F-3ASR
f4tx0fu
7 May 14
Automatic shelf registration (foreign)
12:00am
6-K
j24k4y0r94i6a94 ez1
7 May 14
GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2/3 Clinical Trial of Epidiolex® in the Treatment of Dravet Syndrome
12:00am
6-K
g20yn
17 Mar 14
GW Pharmaceuticals Provides Update on Cannabinoid Pipeline
12:00am
6-K
3tfd xtnue9wsx
12 Mar 14
Current report (foreign)
12:00am
6-K
fb4ncy0gr9x8fi9d7z1
28 Feb 14
GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex® in the Treatment of Lennox-Gastaut Syndrome
12:00am
SC 13G
c5t3x5o3m7t2
13 Feb 14
GW Pharmaceuticals PLC
12:00am
6-K
jbuka
5 Feb 14
GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress
12:00am
6-K
znz9b
16 Jan 14
Current report (foreign)
12:00am